Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$332.15 1.03 (0.31)%
Market Cap 0.00M
02/16/18 4:00 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
Angiogenesis Conference 2018
Feb 10, 2018
Regeneron Pharmaceuticals Q4 2017 Earnings Conference Call
Feb 8, 2018 | 8:30 AM ET